论文部分内容阅读
目的调查幽门螺杆菌阳性患者的药物应用情况,规范幽门螺杆菌阳性患者的药物治疗方案。方法回顾性分析某院2015年6月~2016年5月幽门螺杆菌阳性患者处方药物的应用情况及用药后幽门螺杆菌根除率,用Excel和SPSS19.0软件进行统计分析,多样本率的比较采用χ~2检验。结果共调查189例处方资料,抗幽门螺杆菌药物联用方案以阿莫西林克拉维酸钾+甲硝唑使用例次最多,占59.79%,其次为甲硝唑+左氧氟沙星,占25.93%,单用一种抗菌药物的情况达到10.05%。标准三联疗法98例,根除率71.13%;铋剂四联疗法72例,根除率92.64%,两者比较差异有统计学意义(P<0.001)。在治疗天数方面,标准三联疗法7,10,14 d的根除率分别为65.91%、76.19%、75.00%,铋剂四联疗法7,10,14 d疗程的根除率分别为60.00%、95.00%、95.35%,两方案14 d疗程结果比较差异有统计学意义(P<0.05)。结论本院抗幽门螺杆菌治疗方案还存在一定问题,总体根除率低,铋剂四联疗法14 d方案应进一步推广。
Objective To investigate the drug application in Helicobacter pylori-positive patients and to standardize the medication regimens of Helicobacter pylori-positive patients. Methods A retrospective analysis of a hospital from June 2015 to May 2016 Helicobacter pylori-positive patients prescription drug use and eradication of H. pylori after drug use, Excel and SPSS19.0 software for statistical analysis, the comparison of multiple sample rates Using χ ~ 2 test. Results A total of 189 prescription data were investigated. The combination of anti-Helicobacter pylori and amoxicillin potassium clavulanate + metronidazole was the most frequently used, accounting for 59.79%, followed by metronidazole + levofloxacin (25.93%), single In the case of an antimicrobial drug it reached 10.05%. The standard triple therapy in 98 cases, the eradication rate was 71.13%; 72 cases of bismuth quadruple therapy, eradication rate was 92.64%, the difference between the two was statistically significant (P <0.001). In the treatment days, the eradication rates of the standard triple therapy at 7, 10, and 14 days were 65.91%, 76.19% and 75.00% respectively. The eradication rates of the bismuth quadruple therapy at 7, 10 and 14 days were 60.00% and 95.00% , 95.35% respectively. There was significant difference between the two regimens for 14 days of treatment (P <0.05). Conclusion There are still some problems in the treatment of Helicobacter pylori in our hospital. The overall eradication rate is low. The 14-day bismuth quadruple therapy regimen should be further popularized.